Aclarion has enrolled its first patients in a clinical trial designed to reduce back pain at the Texas Back Institute in Plano.
The chronic low back pain randomized independent trial study (CLARITY) will aim to prove the effectiveness of Nociscan’s ability to improve surgical outcomes for chronic low back pain, according to a June 25 Aclarion news release.
Nociscan utilizes MR spectroscopy and augmented intelligence to identify the source of lower back pain in patients.
The study, which is expected to end in 2026, will evaluate patients who are scheduled to undergo surgical treatment of 1- or 2-level discogenic low back pain.
The study will look at 300 patients who will receive a Nociscan prior to surgery. The primary goal is to reduce patients’ back pain.
The study’s main investigator is Nicholas Theodore, MD, a professor at Johns Hopkins Medicine in Baltimore. Seven sites, including Texas Back Institute, will ultimately enroll patients.
